Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the TAXUS Liberté stent early next month in the United States, following completion of the introduction of its TAXUS® Expresss2™ Atom™ Paclitaxel-Eluting Coronary Stent System, which was approved by the FDA last month. The TAXUS Liberté stent was launched in Europe and other international markets in 2005.

To view Multimedia News Release go to, http://www.prnewswire.com/mnr/bsci/34446/